not traditionally thought to have either genetic causes or even genetic influences. Moreover, the study by Vissers et al. 1 emphasizes that tremendous insights can be gleaned by broadening our thinking and experimental approaches from locus-specific to genome-wide investigations. Indeed, personal genome studies may be the only way to explore some of the most pressing questions in human biology and medicine.
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The author declares competing financial interests. Details accompany the full-text HTML version of the paper at http://www.nature.com/naturegenetics/. of evolution of the human social brain 9 . Of note, both deletion and duplication CNVs at 16p11.2 and 1q21.1 are often found as de novo events, and are reciprocally correlated with head size, in individuals with sporadic neurobehavioral phenotypes including autism and schizophrenia 10, 11 . Is the introduction of variation due to new mutation, or 'evolvab ility' 12 , the price we pay as a species to better adapt brain function to an ever-changing and challenging environment? Beyond human brain development, function and evolution, the recent studies of sporadic mental retardation, autism and schizophrenia hint at a potential prominent role for new mutation in many human diseases, including those 
FTO gains function

George Stratigopoulos & Rudolph L Leibel
Previous genome-wide association studies have identified a strong association between FTO and human obesity, although the mechanism by which FTO affects obesity remains unknown. a new study suggests that the obesity risk alleles are gain-of-function.
In 2007, a genome-wide association study identified the strongest association signal yet reported for an adiposity modifier gene 1 , located in the first intron of FTO (also known as the fat mass and obesity-associated gene) (Fig. 1) . Individuals homozygous for the FTO risk allele eat more 2 and are, on average, ~7 pounds heavier 1 than individuals homozygous for the protective allele. Individuals heterozygous for the risk allele are 3 pounds heavier on average, implying a dose-dependent effect 1 . Although FTO was found to have demethylase activity 3 , this function provided no immediate clues as to the molecular-physiological mechanism by which this gene might affect adiposity.
Some studies have suggested that FTO exerts anorexigenic effects, as fasting (accompanied by an increased drive to eat) is associated with decreased hypothalamic Fto expression in mouse 3, 4 . However, mice segregating a null Fto allele are lean due to increased energy expenditure 5 . These mice also have higher postnatal mortality rates, generalized reduction in body size, hyperphagia and reduced body fat, suggesting that Fto may play a direct role in the development of adipose tissue. In contrast, mice homozygous for a dominant-negative Fto mutation that does not cause increased perinatal mortality or generalized reduction in body size display reduced fat mass, as well as increased energy expenditure without apparent changes in physical activity or food intake 6 . From these studies, it is not clear whether the susceptibility alleles in humans are hypermorphic or hypomorphic with regard to FTO function, whether the impact on obesity is conveyed entirely by effects in the brain or whether the effects on FTO expression differ by organ. On page 1086 of this issue, Roger Cox and colleagues report the first in vivo study that directly addresses the effects of systemic Fto overexpression on food intake and energy expenditure 7 .
FTO gain of function
Church et al. 7 created mice carrying one or two extra copies of a ubiquitously expressed Fto gene, resulting in Fto overexpression in all tissues tested, including white adipose tissue (overexpressed by ~1.5-fold and ~3-fold, respectively) and hypothalamus (overexpressed by ~2-fold and ~2.5-fold, respectively), with the highest levels of overexpression seen in muscle (~3-fold and ~10-fold, respectively). These mice displayed increased energy intake and increased adiposity in a dose-dependent manner, in agreement with fasting 4 , consistent with a role in energy homeostasis. In addition, FTO and RPGRIP1L are co-regulated by CUX1 from a site within the DNA region associated with obesity ( Fig. 1) 4 . Therefore, the function of both FTO and RPGRIP1L may be affected in individuals carrying the obesity risk allele, which may also partly explain the strength of the association.
Thus, the molecular basis for the association of SNPs in intron 1 of FTO with adiposity in humans remains unknown. It is plausible that the locus contains elements that mediate the regulation of both FTO and RPGRIP1L (and, possibly, other more distant genes) and that this regulation involves the hypothalamus, adipocytes and possibly other cell types involved in the regulation of body weight. Tissue-specific underexpression and overexpression of both genes will be required to work out the complex molecular physiology of FTO-associated obesity. The effort is likely to be rewarded by identification of new regulators of body weight.
